Cargando…

Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas

Metastatic pheochromocytomas and paragangliomas (MPPGs) are rare endocrine malignancies that are associated with high rates of morbidity and mortality because of their large tumor burden and location, progression, and release of catecholamines. Systemic therapies for MPPGs are limited. MPPGs are cha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jimenez, Camilo, Subbiah, Vivek, Stephen, Bettzy, Ma, Junsheng, Milton, Denai, Xu, Mingxuan, Zarifa, Abdualrazzak, Akhmedzhanov, Fechukwu Omolara, Tsimberidou, Apostolia, Habra, Mouhammed Amir, Rodon Anhert, Jordi, Fu, Siqing, Naing, Aung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465458/ https://www.ncbi.nlm.nih.gov/pubmed/32824391 http://dx.doi.org/10.3390/cancers12082307

Ejemplares similares

Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma
por: Habra, Mouhammed Amir, et al.
Publicado: (2019)

Phase 2 study of pembrolizumab in patients with advanced rare cancers
por: Naing, Aung, et al.
Publicado: (2020)

Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial
por: Mendoza, Tito R., et al.
Publicado: (2022)

Endocrine and Neuroendocrine Tumors Special Issue—Checkpoint Inhibitors for Adrenocortical Carcinoma and Metastatic Pheochromocytoma and Paraganglioma: Do They Work?
por: Jimenez, Camilo, et al.
Publicado: (2022)

Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory
por: Mendoza, Tito, et al.
Publicado: (2020)

Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers
por: Colen, Rivka R, et al.
Publicado: (2021)

Revisiting Clinical Trials Using EGFR Inhibitor-Based Regimens in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis of an MD Anderson Cancer Center Phase I Population
por: Wheler, Jennifer, et al.
Publicado: (2013)

Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study
por: Thein, Kyaw Z., et al.
Publicado: (2022)

Pheochromocytomas and secreting paragangliomas
por: Plouin, Pierre-François, et al.
Publicado: (2006)

T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy
por: Stephen, Bettzy, et al.
Publicado: (2023)

Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi‐arm phase Ib study
por: Thein, Kyaw Zin, et al.
Publicado: (2021)

Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study
por: Thein, Kyaw Zin, et al.
Publicado: (2021)

Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single‑center, multi‑arm phase Ib study
por: Thein, Kyaw Z., et al.
Publicado: (2021)

Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study
por: Thein, Kyaw Z., et al.
Publicado: (2021)

Pheochromocytoma and paraganglioma: imaging characteristics
por: Baez, Juan C., et al.
Publicado: (2012)

Glycemic Disturbances in Pheochromocytoma and Paraganglioma
por: Ronen, Joshua A, et al.
Publicado: (2019)

Molecular markers of paragangliomas/pheochromocytomas
por: Zhikrivetskaya, Svetlana O, et al.
Publicado: (2017)

Characteristics of Pediatric Pheochromocytoma/paraganglioma
por: Sarathi, Vijaya
Publicado: (2017)

Review of Pediatric Pheochromocytoma and Paraganglioma
por: Bholah, Reshma, et al.
Publicado: (2017)

Preoperative Management of Pheochromocytoma and Paraganglioma
por: Fang, Fang, et al.
Publicado: (2020)

Pheochromocytoma (PHEO) and Paraganglioma (PGL)
por: Pacak, Karel, et al.
Publicado: (2019)

Metastatic Pheochromocytomas and Abdominal Paragangliomas
por: Granberg, Dan, et al.
Publicado: (2021)

Personalized Management of Pheochromocytoma and Paraganglioma
por: Nölting, Svenja, et al.
Publicado: (2021)

Dopamine-Secreting Pheochromocytoma and Paraganglioma
por: Miyamoto, Shotaro, et al.
Publicado: (2021)

Tumour microenvironment in pheochromocytoma and paraganglioma
por: Martinelli, Serena, et al.
Publicado: (2023)

Pheochromocytoma/paraganglioma-associated cardiomyopathy
por: Szatko, Alicja, et al.
Publicado: (2023)

Diagnosis for Pheochromocytoma and Paraganglioma: A Joint Position Statement of the Korean Pheochromocytoma and Paraganglioma Task Force
por: Ku, Eu Jeong, et al.
Publicado: (2021)

Pheochromocytoma/paraganglioma crisis: case series from a tertiary referral center for pheochromocytomas and paragangliomas
por: Meijs, Anouk C, et al.
Publicado: (2021)

Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors
por: Tapia, Coya, et al.
Publicado: (2020)

A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma
por: Nze, Chijioke, et al.
Publicado: (2023)

A spontaneous paraganglioma–pheochromocytoma syndrome
por: Toutounchi, Sadegh, et al.
Publicado: (2013)

Pheochromocytomas and Paragangliomas: Clinical and Genetic Approaches
por: Costa, Marcia Helena Soares, et al.
Publicado: (2015)

Paraganglioma or pheochromocytoma? A peculiar diagnosis
por: Marques, Ricardo Rodrigues, et al.
Publicado: (2018)

New insights on the pathogenesis of paraganglioma and pheochromocytoma
por: Kantorovich, Vitaly, et al.
Publicado: (2018)

Pheochromocytomas and Paragangliomas as Causes of Endocrine Hypertension
por: Canu, Letizia, et al.
Publicado: (2019)

Pheochromocytomas and Paragangliomas: Bypassing Cellular Respiration
por: Cascón, Alberto, et al.
Publicado: (2019)

Molecular Alterations in Dog Pheochromocytomas and Paragangliomas
por: Korpershoek, Esther, et al.
Publicado: (2019)

Pheochromocytoma- and paraganglioma-triggered Takotsubo syndrome
por: Y-Hassan, Shams, et al.
Publicado: (2019)

Postoperative Management in Patients with Pheochromocytoma and Paraganglioma
por: Mamilla, Divya, et al.
Publicado: (2019)

Update on Modern Management of Pheochromocytoma and Paraganglioma
por: Lenders, Jacques W. M., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_re738uab7kiej6f586eip9hopl